Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1998-07-20
1999-11-09
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514654, 514913, A61K 31135
Patent
active
059815981
ABSTRACT:
Methods and kits for treament of glaucoma are disclosed. In general, the methods of the invention include administering a therapeutically effective amount of a deprenyl compound to a subject such that the subject is treated for glaucoma.
REFERENCES:
patent: 4861800 (1989-08-01), Buyske
patent: 5242950 (1993-09-01), Fries Hastings
patent: 5276057 (1994-01-01), Milgram et al.
patent: 5444095 (1995-08-01), Tatton
Ariens, E., "Stereochemistry: A Source of Problems in Medicinal Chemistry," Medicinal Research Reviews, vol. 6, No. 4, 451-66 (1986).
Birkmayer, W. et al.; (1985) "Increased Life Expectancy Resulting from Addition of L-Deprenyl to Madopar.RTM. Treatment in Parkinson's Disease: A Longterm Study"; J. Neural Transmission; 64; pp. 113-127.
Buys, Y.M. et al., "Deprenyl Rescues Retinal Ganglion Layer Cells After Optic Nerve Crush", Investigative Ophthalmology & Visual Science; vol. 35, No. 4, Abstract No. 1062, p. 1484 (1994).
Greenwood, Carol E. et al.; (1991) "Increased Dopamine Synthesis in Aging Substantia Nigra Neurons"; Neurobiology of Aging; vol. 12; pp. 557-565.
Heinonen, E.H.; (1993); "Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of MAO-B in Human Subjects"; Neurology, A156; No. 19P.
Jonakait, G. Miller et al.; (1988) "Development of serotonin, substance P and thyrotrophin-releasing hormone in mouse medullary raphe grown in organotypic tissue culture: developmental regulation by serotonin"; Brain Research, 473; pp. 336-343.
Knoll, J.; ((1983) "The Facilitation of Dopaminergic Activity in the Aged Brain by (--)Deprenyl A Proposal for a Strategy to Improve the Quality of Life in Senescence"; Mechanisms of Ageing and Development; 30; pp. 109-122.
Magyar, K.; (1994); "Behaviour of (--)-deprenyl and its analogues"; J. Neural Transm.; [Suppl]41: pp. 167-175.
Mehra, K. et al., "Pargyline Drops in Glaucoma," Arch Ophthalmol, vol. 92, No. 6, 453-454 (1974).
The Merck Index; (1983) 10th edition, Windholz, M. (Ed.), abstract 2893, p. 423, abstract 6988, p. 1023, abstract 1983; p. 282.
Nickel, B.; (1990); "Effect of selegiline and desmethyl-selegiline on cortical electricity activity in rats"; J. Neural Transm.; [Suppl]32: pp. 139-144.
Rao, T.S,; (1987); "N,N-Dipropargyl-2-Phenylethylamine, A Potential Prodrug of 2-Phenylethylamine: Neurochemical and Neuropharmacological Studies in Rat"; Brain Research Bulletin; vol. 19; pp. 47-55.
Riederer, P. and Youdim, M., "Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with .iota.-Deprenyl," Journal of Neurochemistry, vol. 46, 1359-65 (1986).
Rinne; (1991); "Nigral degeneration in Parkinson's disease in relation to clinical features"; Acta Neurol Scand.; 84 Suppl 136; 87-90.
Rinne et al; (1991); "Seleqiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease"; Neurology; 41; 859-861.
Seniuk et al; (1990); "Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP"; Brain Res.; 527(1); 7-20.
Tatton et at; (1992); "Interactions Between MPTP-Induced and Age-Related Neuronal Death in a Murine Model of Parkinson's Disease"; Can. J. Neurological Sciences; 19; 124-133.
Tatton et al.; (1991) "Different Rates of Age-Related Loss For Four Murine Monoaminergic Neuronal Populations"; Neurobiol. of Aging; 12; pp. 543-556.
Tatton et al; (1990); "MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells"; Brain Res.; 527(1); pp. 21-31.
Timar, Julia; (1989) "Recovery of Mao-B Enzyme Activity After(--)Deprenyl (Selegiline) Pretreatment, Measured In Vivo"; Acta Physiologica Hungarica; vol. 74(3-4); pp. 259-266.
Torok Tamas L. et al; (1987) "Transmitter releasing action of selegiline(--)-deprenyl) from peripheral sympathetic nerves under different experimental conditions"; J. Pharm. Pharmacol.; 39(10); abstract of pp. 797-802, pp. 48 of Chemical Abstracts.
Trope, G.Z. et al., "Deprenyl Improves Visual Function in Glaucoma Patients," Investigative Opthalmology & Visual Science, vol. 35, No. 4, ab. No. 4270-40, p. 2178 (1994).
Zsilla, Gabriella et al.; (1984) "Neurochemical evidences for facilitation of dopaminergic function in rat brain by repeated doses of(--)deprenyl"; Dev. Neurosci. (Amsterdam); 17 (Regular Transm. Funct.: Basic Clin. Aspects); abstract of pp. 345-348; pp. 64 of Chemical Abstracts.
Zsilla, Gabriella et al.; (1986) "The Effect of Repeated Doses of(--)Deprenyl On The Dynamics of Monoaminergic Transmission. Comparison With Clorgyline"; Pol. J. Pharmacol. Pharm.; 38; pp. 57-67.
Zsilla, Gabriella et al.; (1983) "(--)-Deprenyl A Selective Mao `B` Inhibitor Increases [.sup.3 H]imipramine Binding and Decreases .beta.-Adrenergic Receptor Function"; European Journal of Pharmacology; 89; pp. 111-117.
Zsilla, G. and Knoll, J.; (1982) "The Action of(--)Deprenyl on Monoamine Turnover Rate in Rat Brain"; Typical and Atypical Antidepressants: Molecular Mechanisms; pp. 211-217.
International Search Report for PCT/CA96/00087, issued Jul. 5, 1996.
Fay Zohreh
The University of Toronto Innovations Foundation
LandOfFree
Deprenyl compounds for treatment of glaucoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Deprenyl compounds for treatment of glaucoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Deprenyl compounds for treatment of glaucoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1456871